ArticleArrhythmia & electrophysiology review2025
Feasibility of Echocardiography-guided Percutaneous Transapical Lead Implantation for Intraventricular Septal Pacing: Acute and 3-Month Evaluation.
Article in Arrhythmia & electrophysiology review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transvenous lead implantation often faces challenges regarding venous access and lead-related complications. This study evaluated the feasibility and safety of a novel echocardiography-guided percutaneous transapical intraventricular septum (PTAIVS) pacing approach in an animal model. Methods: Twelve adult dogs underwent PTAIVS lead implantation guided by transthoracic and transoesophageal echocardiography. Leads were introduced percutaneously through the apex and fixed in the mid-to-basal septum. The first six dogs were implanted with a pacing set with a coaxial introducer needle (CareFusion) and a Model 3830 lead (Medtronic), whereas an improved pacing set with an extended helix lead was used in the next six dogs. The first three dogs were used for evaluation of acute gross pathology, with the remaining nine followed up over a period of 4-12 weeks. Pathological examinations were performed at the end of the follow-up period. Results: Successful lead placement without procedural complications was achieved in all dogs, with a mean (± SD) procedural time of 28.8 ± 4.8 min. At implantation, the median (interquartile range) capture threshold was 1.7 (0.85-2.50) V, the R-wave amplitude was 6.80 (6.13-13.00) mV and impedance was 536 (510-922) Ω. In the initial six dogs in which the unmodified pacing system was used, lead dislodgement occurred at the 1-month follow-up. Modifications to the system eliminated dislodgement at 1 month, but varying degrees of displacement were observed by 3 months. Conclusion: This study demonstrates the initial technical feasibility of echocardiography-guided PTAIVS pacing, offering a potential alternative to traditional transvenous methods. However, further refinements are essential to improve long-term lead stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.